REC Ref No.	IRAS No.	Name of Trial	Date First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
21/WA/0195	294538	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven,			08/06/2021						
20/LO/1285	285539	Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA) Phase 3 study evaluating the safety and efficacy of an			28/05/2021						
	20000	investigational drug (Debio 1143) in combination with standard platinum-based concomitant chemoradiotherapy for patients who are treatment naive, inoperable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)			20/00/2021						
21/LO/0467	300194	A dose confirmation study of FLT180a (adeno-associated viral vector containing the Padua variant of a codon-optimized human Factor IX gene) in adult subjects with hemophilia B - FLT180a-06			29/06/2021						
21/NW/0186	1003821	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)			14/06/2021						
21/LO/0216	292031	Duroplasty for Injured cervical Spinal Cord with Uncontrolled Swelling		15/06/2021	16/06/2021	24/05/2021					
21/NW/0039	294490	A Modu lar, Ph ase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care			15/06/2021						
20/EE/0293	276366	Vitrectomy and subretinal TPA for submacular haemorrhage secondary to wet AMD (TIGER)			10/06/2021	19/02/2021					
20/WM/0219		Multi-Centre, open-label, randomised, prospective trial to assess efficacy and safety of the CADDIE artificial intelligence system for improving endoscopic quality			22/06/2021						
20/SC/0277	281231	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS		14/05/2020	20/05/2021						

18WA0199	108978	AZTEC: Azithromycin Therapy for Chronic Lung Disease of Prematurity			14/05/2021					
		A randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease								
20/NW/0340	1003335	A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE- BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS	1	10/05/2021	15/06/2021	18/09/2020				
20/SC/0403	288652	PROphylaxis for paTiEnts at risk of COVID-19 infecTion	0	05/05/2021	05/05/2021		06/07/2021	05/07/2021		
21/FT /0050	294543	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)	2	29/04/2021	01/06/2021	20/05/2021				
21/FT/0049	294544	A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)	1	12/03/2021	24/05/2021	20/05/2021				
	239796	Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer			05/05/2021					
21/EM/0102	294776	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	1	19/05/2021	14/05/2021					
19/SW/0209	257547	Proper Understanding of Recurrent Stress Urinary Incontinence Treatment in Women: A Randomised Controlled Trial of Endoscopic and Surgical Treatment	1	19/04/2021	21/04/2021					Sponsor
20/LO/0027	263262	CONCEPT STUDY: COmparing the effectiveness of phacoemulsificatioN + ECP lasEr and Phacoemulsification alone for the treatment of primary open angle glaucoma in patients with cataract – a randomised controlled Trial	1	16/04/2021	12/05/2021	24/02/2020	28/06/2021	29/06/2021		
21/WS/0036	1003558	A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) â€" The COASTAL Study	2	21/10/2020	21/04/2021					Sponsor
21/NI/0032	1003609	A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB	0	08/03/2021	20/04/2021					NHS Provider
	294861	HElping Alleviate the Longer-term consequences of COVID-19(HEAL-COVID): a national platform trial			30/04/2021		05/07/2021	05/07/2021	08/07/2021	
19/WA/0019		Reduction Of Surgical Site Infection using several Novel Interventions	3	31/03/2021	07/04/2021					Sponsor
20/HRA/6152		The LAVA (Lateral flow Antigen Validation and Applicability) 2 Study for COVID-19			21/04/2021					NHS Provider
21/WM/0013	283141	Hysteroscopic Excision of Leiomyoma and Polyp in Infertility	C	04/03/2021	25/05/2021					

		I		1			1	1	1	I	1
21/EE/0055	1003560	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND,		18/03/2021	25/05/2021	05/05/2021					
		PLACEBO-CONTROLLED, MULTICENTER STUDY									
		TO EVALUATE THE EFFICACY AND SAFETY OF									
		INTRAVENOUS PRASINEZUMAB IN									
		PARTICIPANTS WITH EARLY PARKINSON'S									
		DISEASE									
21/EE/0039	290104	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL,		09/02/2021	12/02/2021						NHS Provider
		ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB									
		DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB									
		EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK									
		HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE									
		RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY									
		LYMPH NODES FOLLOWING NEOADJUVANT THERAPY									
		ETWITTHOSEST SEESWING NEO/LOGOVANT THEIR II									
21/SC/0084	293797	A Phase 3 Randomized, Double-Blind, Placebo-Controlled,		05/03/2021	05/03/2021		19/04/2021	06/05/2021		27/05/2021	Neither
		Parallel Group, Multicenter Study Evaluating the Efficacy and									
		Safety of Remdesivir in Participants with Severely Reduced									
		Kidney Function who are Hospitalized for COVID-19									
20/LO/1061	276250	Attentional Therapy for the TrEatment of Neglect Disorder		05/03/2021	07/06/2021		13/07/2021	13/07/2021			
		(ATTEND)									
20/EE/0127	277059	The HUmeral SHaft fracture trial: A multi-centre prospective		16/02/2021	16/02/2021	02/06/2020	07/06/2021	17/06/2021			NHS Provider
		randomised superiority trial of surgical versus non-surgical									
		interventions for humeral shaft fractures in patients aged 18									
		years or older									
21/HRA/0489	294480	OCTAVE: Observational Cohorts Trial - T-cells Antibodies	17/03/2021	17/02/2021	05/03/2021		09/03/2021	09/03/2021		10/03/2021	
		and Vaccine Efficacy in SARS-CoV-2									
21LO0261	291828	Multi-centre, pilot study evaluating the feasibility,			18/05/2021	10/05/2021					
		acceptability and short-term outcomes of a tailored, virtual,									
		home-based, multicomponent prehabilitation programme in									
		patients undergoing abdominal aortic aneurysms (AAA)									
		repair									
20/WS/0171	281799	Physiologic Pacing Registry		28/01/2021	08/02/2021			Site	declined to partic	ipate	
19/WS/0107	256189	A pivotal study of derazantinib in patients with inoperable or			02/03/2021		27/05/2021				Neither
		advanced intrahepatic cholangiocarcinoma and FGFR2 gene									
		fusions or FGFR2 gene mutations or amplifications									
21/WA/0030	293576	A randomised controlled trial of scanning eye training as a		29/01/2021	01/02/2021	12/03/2021	28/05/2021	01/06/2021		01/06/2021	NHS Provider
		rehabilitation choice for hemianopia after stroke (SEARCH)									
21/SS/0007	292045	A Phase III, Multicenter, Open-Label, Randomized Study to		13/10/2020	02/02/2021		08/06/2021	01/07/2021			Neither
		Evaluate the Efficacy and Safety of Belantamab Mafodotin in									
		Combination with Pomalidomide and Dexamethasone (B-Pd)									
		versus Pomalidomide plus Bortezomib and Dexamethasone	I								
		(PVd) in Participants with Relapsed/Refractory Multiple									
		Myeloma (DREAMM 8)									
21/ES/0006	282284	ELEVATE: Temozolomide + nivolumab in MGMT deficient		25/01/2021	25/01/2021			Site	declined to partic	ipate	
		oesophagogastric cancer							,		
21/FT/0058	293068	A Phase 1 Study Exploring the Safety, Tolerability,			18/05/2021						
		Pharmacokinetics, and Pharmacodynamics of INCB099318									
	I	in Participants With Select Advanced Solid Tumors	I	I	ı		I	I		I	1

20/EE/0254	283893	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE			20/01/2021	20/01/2021	10/06/2021	24/06/2021	18/06/2021	Neither
20/66/0254	203093	3 STUDY OF FIRST-LINE ENCORAFENIB PLUS			20/01/2021	20/01/2021	10/00/2021	24/00/2021	10/00/2021	Neithei
		CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY								
		VERSUS STANDARD OF CARE THERAPY WITH A								
		SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB								
		PLUS CHEMOTHERAPY IN PARTICIPANTS WITH								
		METASTATIC BRAF V600E-MUTANT COLORECTAL								
		CANCER								
20/SC/0377	287169	Recombinant Factor VIIa for Acute Hemorrhagic Stroke		03/03/2021	03/03/2021					Sponsor
		Administered at Earliest Time (FASTEST) Trial		/ /				17/22/2221		
20/HRA/6338	293815	A randomised, multicentre post-exposure prophylaxis (PEP)		13/01/2021	19/02/2021			15/03/2021		Neither
		clinical trial evaluating RESP301, an inhaled therapy for treatment of lung infections, for prevention of onward								
		transmission of viral infections including SARS-CoV-2 to								
		household members.								
20/SC/0372	283157	Intramuscular tranexamic acid for the treatment of		05/01/2020	26/05/2021	17/12/2020				
		symptomatic mild traumatic brain injury in older adults: a				,				
		randomized, double-blind, placebo-controlled trial.								
20/EE/0252	276415	Pharmacological management of seizures post traumatic	26/05/2021	11/12/2020	18/12/2020	20/01/2021		07/04/2021	26/04/2021	Neither
17/00/0000	1=001=	brain injury		00// //0000	10/01/0001	00/00/004				
15/SC/0293	178915	Registry of Deep Brain Stimulation with the VERCISEâ,¢		20/11/2020	12/04/2021	03/06/2015				Sponsor
		System for treatment of Dystonia: Vercise DBS Dystonia Registry								
20/SC/0450	291949	A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm,		14/12/2020	03/03/2021					Sponsor
20,00,0100		216 Week Study to Evaluate Efficacy and Safety of		1 17 12/2020	00/00/2021					openioo.
		Treatment With BAN2401								
		in Subjects With Preclinical Alzheimer's Disease and								
		Elevated Amyloid (A45 Trial) and in Subjects With Early								
		Preclinical Alzheimer's Disease and Intermediate								
		Amyloid (A3 Trial)								
20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled		24/12/2020	02/01/2021		16/02/2021	16/02/2021	26/02/2021	Sponsor
		Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-								
10/55/0055	222524	5734TM) Treatment of COVID-19 in an Outpatient Setting		07/10/0000	24/22/2224		00/04/0004	22/24/2224	00/00/000	
	266504	Trial of Ondansetron as a Parkinson's HAllucinations Treatment		07/12/2020			08/04/2021	08/04/2021		Sponsor
20/SC/0111	276734	A Multicenter, Open-Label, Randomized Phase III Study to	23/04/2021	27/11/2020	07/12/2020		01/04/2021	12/04/2021	14/04/2021	Sponsor
		Evaluate the Efficacy and Safety of the Combination of								
		Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-								
		Vd) Compared with the Combination of Daratumumab,								
		Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma								
20/LO/1278	288502	A multicenter, Phase 2a, open-label, non-randomized		26/11/2020	07/12/2020	26/01/2021	28/01/2021	02/02/2021		Neither
20/20/12/0	200302	study evaluating the efficacy, safety, and tolerability of		20/11/2020	01/12/2020	20/01/2021	20/01/2021	02/02/2021		Notifier
		BIVV020 in adults with persistent/chronic immune								
		thrombocytopenia (ITP)-PDY16894								
20/NW/0300	285728	A Phase 3, randomized, double-blind, efficacy and safety		23/11/2020	14/12/2020	15/09/2020				Neither
		study comparing SAR442168 to placebo in participants with								
		nonrelapsing secondary progressive multiplesclerosis								
		(HERCULES)								

				1					
	290807	INTERVENTION 1 PROTOCOL (Xarelto): A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19	04/12/202			11/01/2021	12/01/2021		Neither
21/WA/0103	291833	INTERvention with Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (INTERCEPTavi): â€~Carbon-Dioxide Flushing versus Saline Flushing of Transcatheter Aortic Valves: A Single-centre Randomised Controlled Trial'	22/02/202	1 27/04/2021	20/04/2021	03/06/2021	08/06/2021	08/06/2021	
20/LO/1291	292074	The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis	03/12/202	0 02/03/2021		17/03/2021	13/04/2021	16/04/2021	Neither
21/LO/0203	288725	ORBITA-COSMIC: Coronary sinus reducer Objective impact on Symptoms, MRI Ischaemia and microvascular Resistance	04/02/202	1 29/03/2021	27/03/2021	21/05/2021	21/05/2021	21/05/2021	
20/LO/1129	1003422	A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 â€" platinum resistant disease and are PARP inhibitor naà ve; Cohort 2 â€" had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.		29/06/2021					
20/WM/0297	288227	A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)	09/11/2020	0 04/06/2021					
20/NI/0070	1003313	Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma	07/10/2020	07/06/2021	07/07/2020				
20/WM/0195	268363	A multi-centre phase II trial of GVHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide	27/11/202	30/11/2020		05/03/2021	08/03/2021	17/03/2021	Sponsor
20/NW/0487	289272	Do the results of intra-operative margin assessment correlate 04/06/20 with the output of conventional histology for patient undergoing breast conservation surgery?	021 15/12/2020	0 11/01/2021	18/01/2021	14/05/2021	27/05/2021	01/06/2021	NHS Provider
20/SC/0018	258872	A randomised controlled trial assessing if microsurgical nerve repair offers clinical benefit and cost effectiveness (in terms of patientâ€"reported hand function, sensory recovery and adverse events) over exploration and washout without microsurgical nerve repair in adult patients with recent traumatic digital nerve injury.	07/10/202	25/11/2020	13/02/2020	09/06/2021	21/06/2021		Neither
21/SW/0016	1003529	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH.	15/02/202	1 07/06/2021					

							T	T			
21/LO/0366	290747	Intra-operative ultrasound guided laparoscopic ovarian		19/10/2020	16/06/2021						
		cystectomy (UGLOC) in the management of benign ovarian									
		cysts: Randomised Controlled Trial									
20/LO/1056	277635	Venetoclax or Intensive Chemotherapy for Treatment Of		13/10/2020	12/11/2020		01/04/2021	06/04/2021		01/06/2021	Neither
20/20/1000		Favourable Risk Acute Myeloid Leukaemia: A Molecularly		10/10/2020	12/11/2020		01/01/2021	00/01/2021		01/00/2021	1 (0.0.10)
		Guided Phase 2 Study									
20/NW/0463	1003437	Phase 2 Study of MK-6482 in Participants With Advanced			17/05/2021		19/04/2021	02/06/2021		16/06/2021	
		Renal Cell Carcinoma			, 00, 202.			02/00/2021		. 0, 0 0, 202 .	
21/LO/0051	285417	Diagnosis of Heart Failure in the Post-COVID-19 Clinic,	15/04/2021	19/10/2020	29/03/2021	05/02/2021	13/04/2021	15/04/2021		15/04/2021	
		Primary Care and Hospital Setting Using a Digital									
		Stethoscope with AI ECG									
20/LO/0840	264482	Functional and Ultrasound guided Resection of		16/10/2020	30/04/2021	05/10/2020		12/05/2021			
		Glioblastoma. A two stage trial. Stage 1 – Non-randomised									
		collaborative learning and evaluation phase of participating									
		centres (IDEAL Stage 2b study), followed by Stage 2 – A									
		Multicentre Phase III trial with 2 mechanistic substudies.									
20/LO/0196	271343	PreOperative Endocrine Therapy for Individualised Care with		05/10/2020	29/04/2021	08/07/2020	29/04/2021	08/07/2021			
		Abemaciclib									
20/LO/1157	281627	An open-label, randomized, controlled phase 3 study of			04/12/2020						Neither
		enfortumab vedotin in combination with pembrolizumab with									
		or without chemotherapy, versus chemotherapy alone in									
		previously untreated locally advanced or metastatic urothelial									
		cancer									
20/LO/1106	286152	Phase 1b, Multicentre, Multiple Ascending Dose, Safety,		23/09/2020	11/01/2021		05/02/2021	09/04/2021		26/04/2021	Neither
		Pharmacokinetic, and Pharmacodynamic Study of									
		Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-									
		grade Serous Ovarian Cancer (HGSOC) Patients						-			
18/NW/0644	248582	A prospective open label, pharmacokinetic study of an oral		24/09/2020	05/11/2020			Site	declined to partic	ipate	
00/00/04/17	22225	hydroxyurea solution in children with sickle cell anemia		0=11010000	1=11110000						A.1. 1/1
20/SC/0117	269627	A two-year, phase III randomized, double-blind, parallel-		27/10/2020	17/11/2020						Neither
		group, placebo-controlled trial to evaluate the safety,									
		efficacy, and tolerability of 300 mg s.c. Secukinumab versus									
		placebo, in combination with SoC therapy, in patients with									
40/55/0004	075750	active Lupus Nephritis (SELUNE)		04/00/0000	44/00/0004	00/04/0000					Ni a itia a a
19/EE/0384	275752	VenaSeal Spectrum: Global, Post-Market, Prospective, Multi-		01/09/2020	11/02/2021	06/04/2020					Neither
		Center, Randomized Controlled Trial of the VenaSealâ,¢									
		Closure System vs. Surgical Stripping or Endothermal									
		Ablation (ETA) for the Treatment of Early and Advanced									
21-YH-0056	283442	Stage Superficial Venous Disease			30/06/2021	08/04/2021					
21-111-0056	203442	Prediction of Patient Drug Response Using an Ex Vivo Organ			30/00/2021	00/04/2021					
		Culture (EVOC) on fresh human tumour samples from Metastatic Patients									
20/LO/1115	286901	Phase 2, Double-blind, Randomized, Placebo-controlled		04/04/2021	19/05/2021						
20/20/1113	200901			04/04/2021	19/03/2021						
		Study of HepTcell (Adjuvanted FP-02.2) as an									
		Immunotherapeutic Vaccine in Treatment naÃf¯ve									
		Patients with Inactive Chronic Hepatitis B (CHB)									

20/LO/0848	272164	ALLTogether1 – A Treatment study protocol of the			02/06/2021					
20/20/0040	272104	ALLTogether Consortium			02/00/2021					
		for children and young adults (1-45 years of age) with newly								
		diagnosed acute								
		lymphoblastic leukaemia (ALL)								
20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3	30/11/2020	30/10/2020	30/10/2020		13/11/2020	16/11/2020	23/11/2020	
		Study to Assess the Efficacy and								
		Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-								
		mediated COVID-19 in Adults								
		Aged 18 Years and Older								
20/NE/0283	286210	An Open-Label, Randomized, Controlled, Phase 2 Study to		28/01/2021	13/04/2021		28/04/2021	29/04/2021		Neither
		Evaluate the Safety and Efficacy of APL-2 in the Treatment								
		of Post-Transplant Recurrence of C3G or IC-MPGN								
20/LO/0504	1003208	Randomised controlled trial of Gestational treatment with		16/09/2020	29/06/2021					
		Ursodeoxycholic Acid compared to Metformin to Reduce								
		effects of Diabetes mellitus								
21/SC/0094	289344	A phase I study to determine safety and immunogenicity of		16/03/2021	16/03/2021	22/04/2021				Sponsor
		the candidate COVID-19 vaccine ChAdOx1 nCoV-19								
		delivered by aerosol in healthy adult volunteers								-
20/SW/0117	1003162	Randomized, Double-Masked, Active-Controlled, Phase 3		15/09/2020	06/11/2020	01/09/2020				Sponsor
		Study of the Efficacy and Safety of High Dose Aflibercept in								
		Patients With Neovascular Age-Related Macular								
00/514/0000	000000	Degeneration (Delice of Delice of De	47/05/0004		40/04/0004	40/00/0004		40/05/0004	4.4/05/0004	
20/EM/0298	283692	Ultrasound Prediction of Delivery Mode: can the first stage prediction model be further improved?	17/05/2021		12/04/2021	18/02/2021		12/05/2021	14/05/2021	
20/WA/0343	273080	Transplant Renal Artery Stenosis Observation versus		26/11/2020	27/11/2020	21/12/2020	01/02/2021			Neither
20, 77, 400 10	2,0000	Stenting		20/11/2020	2771172020	21/12/2020	01/02/2021			T TORTION
21/PR/0250	281309	Neuromuscular Stimulation for Rehabilitation after general		11/09/2020	13/05/2021	12/05/2021	07/07/2021	07/07/2021	07/07/2021	
		and vascular surgery - a pilot randomised clinical study								
20/LO/1272	287235	A prospective randomised extended pilot study of a directed	02/07/2021		25/03/2021	25/03/2021		13/04/2021	13/04/2021	Sponsor
		psycho-educational tool to prevent psychological sequelae								
		following Paediatric Intensive Care admission								
20/LO/0009	263698	Observational cohort with embedded Randomised Controlled		24/08/2020	05/01/2021		09/02/2021	09/02/2021	19/04/2021	Neither
		trials to study pregnancy-Associated progression of Renal								
		Disease – A Feasibility Study of Dietary Nitrate (BEETroot								
		juice) to protect kidney function in pregnant women with								
		Chronic Kidney Disease								
20/SS/0072	255036	A Long-term Follow-up Study of Subjects With		30/07/2020	14/08/2020	11/09/2020	05/02/2021	06/04/2021	07/04/2021	Neither
		β-thalassemia or Sickle Cell Disease Treated with								
		Autologous CRISPR-Cas9 Modified Hematopoietic								
17/NW/0078	22222	Stem Cells (CTX001)			16/06/2021					
	220323	Product Surveillance Registry - NeuroVascular				0=/04/0004	00/00/000			
20/LO/1297	288071	Impact of the short chain fatty acid propionate on mesenteric			08/03/2021	25/01/2021	08/03/2021			Sponsor
		adipose tissue, liver metabolism and insulin sensitivity: The								
20/MS/0422	207640	PROMIS study.	17/12/2020		26/11/2020	24/11/2020		00/42/2020	10/12/2020	
20/WS/0133	20/010	Bioimpedence and Arterial function Monitoring at Birth and in Infants: the BAMBI study	17/12/2020		26/11/2020	24/11/2020		09/12/2020	10/12/2020	
20/WA/0197	284509	Validation of PAT for pre-operative screening for OSA	08/10/2020	04/08/2020	25/08/2020		02/07/2020	21/09/2020	21/09/2020	
	1	The special content of	130, .0, 2020	1 ., 30, 2020	_0,00,2020		0_,0,,_0_0	I = ., 00, 2020	, 00, _020	1

00/55/0450	40000=5	INATIC CONTRACTOR OF THE CONTR	05/04/000:	00/05/000	47/00/000	00/07/0000	10/11/2000	04/40/2222	 00/40/2022	اما
20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	05/01/2021	20/05/2020	17/09/2020	29/07/2020	13/11/2020	01/12/2020	09/12/2020	Sponsor
18/WA/0420	246637	Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women			13/04/2021	04/02/2019		13/05/2021	21/05/2021	Neither
20/LO/1111	286572	Prospective Evaluation to Characterize the Realâ€World PerFormance of the EMBOVACTM Aspiration Catheter for Neurothrombectomy: A Postâ€Market Clinical Followâ€up Trial.	04/06/2021	21/07/2020	18/03/2021		13/04/2021	19/04/2021	24/05/2021	Sponsor
20/EM/0003	269023	Multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress.	13/12/2020	14/07/2020	14/07/2020		24/11/2020	02/12/2020	07/12/2020	Sponsor
20/NE/0169	279315	Clinical trial of SARS-CoV-2 vaccine in healthy men and women - COVAC1	27/07/2020		03/07/2020		21/07/2020	21/07/2020		
21/NI/0009	278082	Accuracy of ECG-guided tip placement and point of care ultrasound scan (POC-US) during central line insertion in neonates – a feasibility study CLIN study	23/06/2021		04/02/2021	27/01/2021		25/05/2021	25/05/2021	Neither
20/LO/0745	273024	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors			09/03/2021	09/06/2020	30/03/2021	31/03/2021	07/04/2021	Neither
20/YH/0268	200925	An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection		06/07/2020	05/05/2021					
20/EE/0204	287569	·	17/02/2021	24/08/2020	24/08/2020		04/11/2020	24/11/2020	25/11/2020	Neither
20/NW/0312	284188	A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Heart Failure or Cardiovascular Death in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure.		22/10/2020	15/06/2021	23/07/2020				
	285961	A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cance		01/12/2020						Neither
20/WM/0221	285758	LumenEye during CovID-19 (LuCID study)			05/02/2021	10/09/2020				Sponsor

20/SW/0087	1003056	EPITOPE OPEN-LABEL EXTENSION STUDY TO		31/03/2020	29/07/2020		01/10/2020	28/10/2020			Sponsor
		EVALUATE THE LONG-TERM CLINICAL BENEFIT AND									
		SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)									
20/HRA/3414	284196	,	09/10/2020		14/09/2020	19/08/2020		05/10/2020		05/10/2020	
		system and the coagulopathy associated with COVID-19									
20/NI/0086	1003261	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-		25/11/2020	25/11/2020						Neither
		CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN									
		PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS									
		NEPHRITIS									
20/LO/0821	281982	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO		02/05/2021	25/05/2021			28/06/2021			
		EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY									
		OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE									
		PARTICIPANTS WITH ALZHEIMER'S DISEASE									
19/NE/0110	257719	A randomised, double-blind, placebo-controlled, cross-over	19/05/2021	28/05/2020	08/07/2020	04/12/2019	16/12/2020	04/01/2021		05/01/2021	Sponsor
		trial of zibotentan in microvascular angina									
20/LO/0906	1003020	A Phase 2b, open-label, single-arm study of ZW25		06/04/2020	09/03/2021		08/12/2020	14/04/2021		28/04/2021	Neither
		monotherapy in subjects with advanced or metastatic HER2- amplified biliary tract cancers									
20/LO/1001	282291	A Phase 1 Study Exploring the Safety, Tolerability,	16/12/2020	23/04/2020	26/10/2020	23/10/2020	19/11/2020	08/12/2020		08/12/2020	
_0,_0,.00.		Pharmacokinetics, and Pharmacodynamics of INCB086550			20/10/2020	_0, . 0, _0_	. 6,, 2020	30, 12, 2020		00/12/2020	
		in Participants With Advanced Solid Tumors									
20/LO/1070	279091	,	02/03/2021	04/11/2020	16/11/2020			01/02/2021		01/02/2021	Neither
		operation on people with type 2 diabetes mellitus?									
		The LONG LIMB-2 double-blinded randomised controlled clinical trial									
20/EM/0036	278520	A Phase 2 Multi-Center, Open Label Study to Assess the		24/03/2020	06/07/2020		30/06/2020	20/07/2020		03/11/2020	Neither
		Safety, Efficacy and Pharmacodynamics of IMG-7289 in									
		Patients with Essential Thrombocythemia.									
20/NW/0230	278525	A Phase 3, Multinational, Randomized, Open-Label, Three		27/04/2020	20/01/2021	18/06/2020	15/02/2021	25/02/2021		12/03/2021	Neither
		Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG									
		Induction With or Without BCG Maintenance) Versus BCG									
		(Induction and Maintenance) in Participants with High-Risk,									
		BCG-NaÃ- ve Non-Muscle Invasive Bladder Cancer									
20/LO/0856	1003178	A Phase 2, randomized, open-label three-arm clinical study		01/04/2020	28/09/2020	18/09/2020	30/11/2020	18/12/2020		23/12/2020	Neither
		to evaluate the safety and efficacy of lenvatinib (E7080/MK-									
		7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy									
		in participants with recurrent/metastatic head and neck									
		squamous cell carcinoma (R/M HNSCC) that have									
		progressed after platinum therapy and immunotherapy (PD-									
		1/PD-L1 inhibitors) (LEAP-009)									
20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter		29/10/2019	15/04/2021	25/09/2020	29/03/2021	05/05/2021		05/07/2021	Sponsor
		trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with									
		established cardiovascular disease.									
	ļ	Cotabilotion outdiovaccular alcoacc.									<u> </u>

00/1 0/4000	005455			44/05/0000	00/00/0004	00/44/0000				
20/LO/1008	285155	A Phase 2, Randomized, Double-Blind, Placebo-Controlled,		11/05/2020	08/06/2021	23/11/2020				
		Multi-Center Clinical Study to Evaluate the Efficacy and								
		Safety of Oral Inhalation of GB002 for the Treatment of WHO								
		Group 1 Pulmonary Arterial Hypertension (PAH).								
20/SC/0371	286893	A Phase 111, Randomised, double-blind, Placebo-controlled		04/09/2020	18/05/2021	09/12/2020	18/06/2021	24/06/2021	24/06/2021	
		study of Atezolizumab with or without Tiragolumab (anti-tigit								
		antibody) in Patients with Unresectable Esophageal								
		Squamous Cell Carcinoma whose cancers have not								
		progressed following definitive Concurrent								
		Chemoradiotherapy.								
20/NW/0189	280629	Clinical Evaluation of the LOIS Smartband	01/03/2021	03/05/2020	23/09/2020		14/12/2020	14/12/2020	14/12/2020	Neither
		in patients undergoing elective								
		ICD implantation with defibrillation								
		threshold testing								
21/LO/0054	283483	A MULTICENTRE PILOT RANDOMISED CONTROL TRIAL			22/06/2021	21/05/2021				
21/20/0001	200 100	OF AN ADAPTED MOBILE REHABILITATION SYSTEM			22/00/2021	21/00/2021				
		FOR SELF-DIRECTED REHABILITATION AND IMPROVED								
		UPPER LIMB OUTCOMES IN STROKE SURVIVORS WITH								
		UPPER LIMB WEAKNESS								
19/WA/0197	256241	WHITE 9- BeST: World Hip Trauma Evaluation 913/4 Blood		22/04/2020	31/08/2020	02/09/2019				Neither
19/00/4/019/	250241	Cell Salvage Trial.		23/04/2020	31/00/2020	02/09/2019				Neithei
		A multi centre randomised controlled trial comparing intra								
		· ·								
		operative cell salvage with standard care in the treatment								
		OT								
00/55/0440	000044	hip fractures.	0.4/4.4/0.000	00/04/0000	04/00/0000		40/40/0000	00/40/0000	0.4/4.4/0.000	
20/EE/0118	283014	A phase III prospective, interventional, cohort, superiority	04/11/2020	23/04/2020	21/09/2020		16/10/2020	28/10/2020	04/11/2020	
		study to evaluate the benefit of rapid COVID-19 genomic								
		sequencing (the COVID-19 GENOMICS UK project) on								
		infection control in preventing the spread of the virus in								
		United Kingdom NHS hospitals								
20/EM/0087	274214	An open-label, randomised, multicentre, phase III study of	10/05/2021	01/04/2020	05/03/2021	19/05/2020	28/01/2021	20/04/2021	28/04/2021	
		irinotecan liposome injection, oxaliplatin, 5-								
		fluorouracil/leucovorin versus nab-paclitaxel plus								
		gemcitabine in subjects who have not previously received								
		chemotherapy for metastatic adenocarcinoma of the								
		pancreas.								
19/LO/0288	235544	A Randomised Placebo-Controlled Trial on the effectiveness		03/09/2020	24/02/2021	09/07/2020		14/05/2021		sponsor
		of Escitalopram and Nortriptyline for depressive symptoms in								
		Parkinson's disease								
20/NW/0181	238013	A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL,		07/04/2020	17/11/2020		04/02/2021	12/04/2021	20/05/2021	Sponsor
		SEQUENTIAL COHORT TRIAL TO EVALUATE THE			, , , , , , , , ,					
		EFFICACY, SAFETY, TOLERABILITY AND								
		PHARMACOKINETICS OF PF-06730512 FOLLOWING								
		MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL								
		SEGMENTAL GLOMERULOSCLEROSIS (FSGS)								
		SEGIVIENTAL GLOIVIERULUSULERUSIS (FSGS)								

19/YH/0307	264579	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, DOSE-FINDING STUDY		02/04/2020	13/04/2021			Sponsor d	leclined site confirmation	Neither
		TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS								
20/EE/0078	267074	A Phase 3 multicentre, double-blind, randomized, placebo- controlled study to evaluate the efficacy, safety, and tolerability of Rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP)- TP0003		20/03/2020	03/11/2020		01/04/2021	24/05/2021	25/05/2021	Neither
21/EM/0019	273631	Improving implantable cardioverter defibrillator arrhythmia detection: development of a novel arrhythmia detection algorithm	05/07/2021	29/12/2020	21/04/2021	30/03/2021	05/07/2021	05/07/2021		sponsor
18/WM/0270	239150	Multicentre, Open-label Randomised Trial of Superficial Wound Drain on Surgical Site Infection in high Body Mass Index (BMI) Kidney Transplants Recipients.		02/07/2020	05/08/2020		25/11/2020	30/11/2020	09/07/2021	Neither
19/EE/0042	257583	A PHASE III, MULTINATIONAL, MULTICENTER, INVESTIGATOR-MASKED, RANDOMISED, ACTIVE-CONTROLLED TRIAL, COMPARING THE EFFICACY AND SAFETY OF DE-130A WITH XALATAN® IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION OVER A 3-MONTH PERIOD, FOLLOWED BY A 12-MONTH FOLLOW-UP WITH OPEN-LABEL DE-130A TREATMENT.		05/03/2020	08/09/2020	12/04/2019	13/08/2020	06/10/2020	04/11/2020	Neither
20/SC/0116	272955	Brain connectivity and patient reported outcomes in people with HIV with symptoms of insomnia switching integrase inhibitor-based ART; a randomised controlled study		02/03/2020	08/04/2021		05/05/2021	12/05/2021	08/07/2021	Sponsor
20/LO/0197	277125	An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies		18/02/2020	23/07/2020	27/03/2020	10/10/2020	20/10/2020	17/11/2020	Neither
20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205	26/04/2021	13/07/2020	22/07/2020		23/12/2020	23/12/2020	23/12/2020	Neither
20/LO/0411	278196	A randomised, placebo controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of a continuous subcutaneous infusion of G3215 in adult subjects	01/12/2020	10/09/2020	10/09/2020		28/09/2020	29/09/2020	29/10/2020	Neither
20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease		20/02/2020	04/06/2021					

19/LO/1898	275312	A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)	01/06/2021	10/02/2020	24/08/2020		15/10/2020	12/01/2021	04/03/2021	Neither
20/WS/0057	277361	Erythropoietin and Darbepoetin in Neonatal Encephalopathy (EDEN) Trial		01/06/2020	30/03/2021	27/05/2020	27/05/2021	28/05/2021	28/05/2021	Sponsor
19/EE/0379	269900	IPX203-B16-03		01/06/2020	17/12/2020	11/10/2019	02/02/2021	02/02/2021		Neither
19/LO/1953	271361	Efficacy of BIC/F/TAF versus standard of care in the treatment of new HIV infection diagnoses in the context of â€⁻test and treat'			25/05/2021		25/05/2021	01/06/2021	09/06/2021	
20/LO/0355	275910	A Physiological Study of the Effect of Î'lpha-MSH on Glucose Clearance and Insulin Sensitivity in Healthy Participants	26/10/2020	25/08/2020	10/09/2020	20/05/2020		20/10/2020	20/10/2020	
20/EE/0031	275993	Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke	10/12/2020	20/12/2019	23/07/2020		23/09/2020	28/10/2020	03/11/2020	Neither
19/LO/1892	272434	A multicenter, randomized, active-controlled, double-blind, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless).		01/01/2020	13/01/2021	21/01/2020	19/04/2021	19/04/2021		Sponsor
20/LO/0364	274161	Minimally Invasive Realtime Assessment of Continuous Lactate in Exercise (MIRACLE)		10/02/2020	02/11/2020	07/05/2020	15/02/2021	15/02/2021	16/02/2021	Neither
19/NW/0707	272541	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)	24/06/2021	29/11/2019	02/04/2021		14/01/2021	10/05/2021	28/05/2021	Neither
20/LO/0477	254910	Psychology of pregnancy of unknown location (SOUL)	02/12/2020	06/02/2020	26/10/2020	23/07/2020	02/11/2020	30/11/2020	30/11/2020	
20/LO/0068	274808	Pre-conception interventions to reduce blood pressure before	02/11/2020	09/10/2020	15/10/2020			30/10/2020	02/11/2020	
18/WS/0218	252602	An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)		25/10/2019	20/11/2020	25/09/2019	26/06/2020	09/12/2020	09/12/2020	Neither
19/LO/0329	252963	A randomised, blinded, controlled, Phase 2a study to evaluate the safety and efficacy of administering Regadenoson to patients with critical injury and signs of haemorrhagic shock		07/10/2019	14/08/2020	02/10/2019	07/10/2019	14/08/2020		Sponsor
19/SC/0634	252084	TREAT Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab		04/05/2020	13/05/2021	04/08/2020				
19/YH/0049	258945	A phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics effects of a single dose of MTPS9579A in patients with asthma requiring inhaled corticosteroids and a second controller		19/08/2020	02/03/2021		01/06/2019	17/06/2021	05/07/2021	Sponsor

19/SW/0043	235625	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease): A phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.	16/06/2021	11/09/2019	18/03/2021	26/06/2019		08/04/2021	12/05/2021	Sponsor
20/LO/0031	266400	Perinatal and 2 year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 Randomised Trial	08/10/2020	14/02/2020	18/09/2020	04/02/2020		01/10/2020	02/10/2020	
19/LO/1064	260639	The TIGHT-K STUDY. Prevention of dysrhythmias on the cardiac intensive care unit - does maintenance of high-normal serum potassium levels matter?	16/06/2021	15/11/2019	19/04/2021	06/11/2019	26/04/2021	28/05/2021	04/06/2021	
19/LO/1449	269837	Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced/Unresectable Biliary Tract Carcinoma		04/07/2019	05/10/2020	24/03/2020	10/11/2020	26/11/2020	13/01/2021	Sponsor
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancy harboring activating FGFR mutations and translocations		02/05/2019	27/04/2021	16/08/2019	22/11/2019	06/05/2021	06/05/2021	
20/LO/0474	266759	Psilocybin as a Treatment for Restrictive Anorexia Nervosa: A Pilot Study	28/05/2021	09/12/2020	11/01/2021	23/06/2020	12/04/2021	12/04/2021	12/04/2021	Neither
19/LO/1669	266322	The RIO Trial: A randomised controlled trial of dual long- acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART-only in treated primary HIV infection - A two-stage randomised phase II placebo controlled clinical trial		14/01/2020	16/04/2021	12/12/2019	05/05/2020	10/05/2021	13/05/2021	Neither
17/NW/0581	214739	Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial		17/04/2019	17/05/2021					
19/SC/0583	258210	Non invasive optic techniques in neurosurgery	28/03/2021		18/09/2020			13/11/2020		Sponsor
19/LO/0836	262145	INTERvention with Cerebral Embolic Protection in TEVAR (InterCEPT): â€~Carbon-Dioxide Flushing versus Saline Flushing of Thoracic Aortic Stents: A Multi-centre Randomised Controlled Trial'		22/02/2019	07/06/2021	07/06/2021				
20/LO/0938	1003322	A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible		07/10/2019	09/03/2021	13/11/2020	02/11/2020	18/05/2021	02/07/2021	Neither
19/SC/0144	226984	Defining personalised outcomes in pre-school children with recurrent wheeze			24/02/2021	31/05/2019		19/05/2021	25/05/2021	Neither
19/LO/0418	259170	Singing for Health: Improving Experience of Lung Disease (SHIELD)	22/06/2021	07/02/2019	24/11/2020	23/05/2019	07/02/2019	16/12/2020	17/12/2020	Neither

20/LO/0345		A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (ADVANCE Capacity)		25/02/2020	31/03/2021	19/06/2020				Neither
20/PR/0378	280354	Arginine Supplementation to improve Cardiovascular and	10/06/2021	27/04/2020	12/04/2021	12/01/2021	28/07/2020	15/04/2021	17/04/2021	
19/EE/0027	252781	PresSura Assessment of NK1 Inhibition in Traumatic Brain		14/02/2019	15/06/2021	15/10/2019				
		Injury in a Global Efficacy and Safety Trial								